Androgen deprivation therapy as primary treatment for prostate cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 2, 2012, Pages 360-365

  Cannata, Dara H ^a   Kirschenbaum, Alexander ^a   Levine, Alice C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; BICALUTAMIDE; CALCITRIOL; CARBOPLATIN; DOCETAXEL; LEUPRORELIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ZOLEDRONIC ACID;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE SCINTISCANNING; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DECREASED APPETITE; DRUG MEGADOSE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; LYMPHADENITIS; MALE; NEEDLE BIOPSY; PARAAORTIC LYMPH NODE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TRANSURETHRAL RESECTION; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ENDOCRINOLOGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; NEOADJUVANT THERAPY; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84856770496     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2353     Document Type: Article

References (30)

1. Andriole GL, Crawford ED,Grubb3rd RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD 2009 Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A,Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A 2009 Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424 (Pubitemid 19211484)
4. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson Jr IM, Bueschen AJ, Lowe BA 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042 (Pubitemid 28457865)
5. Huggins C, Hodges CV 2002 Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168:9-12
6. Byar DP 1973 Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32:1126-1130
7. 1984 Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group.NEngl J Med 311:1281-1286
8. Huggins C, Scott WW 1945 Bilateral adrenalectomy in prostatic cancer. Ann Surg 122:1031-1041
9. Moguilewsky M, Fiet J, Tournemine C, Raynaud JP 1986 Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem 24:139-146 (Pubitemid 16047768)
10. Labrie F, Dupont A, Belanger A, Lefebvre FA, Cusan L, Monfette G, Laberge JG, Emond JP, Raynaud JP, Husson JM, Fazekas AT 1983 New hormonal treatment in cancer of the prostate: combined ad ministration of an LHRH agonist and an antiandrogen. J Steroid Biochem 19:999-1007
11. 2000 Maximumandrogen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355:1491-1498
12. Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC 2007 Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res 67:5747-5753 (Pubitemid 46985007)
13. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L 2009 Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516-2527
14. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU 2011 Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365:107-118
15. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL 2009 Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-1209
16. Shahinian VB,KuoYF, Gilbert SM 2010 Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 363:1822-1832
17. Niraula S, Tannock IF 2011 Broadening horizons in medical management of prostate cancer. Acta Oncol 50(Suppl 1):141-147
18. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39 (Pubitemid 38524696)
19. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS 2004 The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448 (Pubitemid 38173980)
20. Mostaghel EA, Plymate S 2011 New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am 40:625-642, x
21. Geller J, Liu J, Albert J, Fay W, Berry CC, Weis P 1987 Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clin Endocrinol (Oxf) 26:155-161 (Pubitemid 17015701)
22. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415
23. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454
24. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825
25. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ 2004 Antiandrogen withdrawal alone or in combination with ketoconazole in androgenindependent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033 (Pubitemid 41095034)
26. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI 2011 Abiraterone and increased survival in metastatic prostate cancer.NEngl JMed364:1995-2005
27. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL 2010 Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437-1446
28. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913-5925
29. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K,TamT, Yang YC, Bañuelos CA, Williams DE, McEwan IJ, Wang Y, SadarMD2010 Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:535-546
30. Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, Chen Z, Chen H, Clinton SK, Chan KK, Wang Q 2011 CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res 71:4866-4876